Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Christopher Wård et al.|New England Journal of Medicine|2024Cited by 162
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Paweł Robak et al.|Journal of Clinical Oncology|2024Cited by 21